Fate Therapeutics (FATE) Debt/Equity Ratio: History & Chart

Fate Therapeutics, Inc.(FATE)

Biotechnology · San Diego, CA

$2.36-0.07 (-2.84%)

Delayed quote: Oct 6, 2026, 12:40 PM EDT

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

San Diego, CA

161 employees

www.fatetherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bahram Valamehr

View full financials

FATE Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.49

DEBT TO EQUITY RATIO AVG TTM

0.39

DEBT TO EQUITY RATIO AVG 3Y

0.30

DEBT TO EQUITY RATIO AVG 5Y

0.24

DEBT TO EQUITY RATIO AVG 10Y

0.23

DEBT TO EQUITY RATIO AVG 15Y

0.24

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+26.72%

CURRENT VS 3Y AVG

+66.26%

CURRENT VS 5Y AVG

+102.13%

CURRENT VS 10Y AVG

+116.02%

CURRENT VS 15Y AVG

+108.99%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.12

median of 681 covered companies

CURRENT VS SECTOR MEDIAN

+311.00%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Fate Therapeutics, Inc. (FATE)	$275.21M	0.49	0.39	0.30	0.24
Rocket Pharmaceuticals, Inc. (RCKT)vs ›	$273.53M	0.07	0.07	0.06	0.07
Scribe Therapeutics Inc. (SCTX)vs ›	$270.48M	N/A	N/A	N/A	N/A
SAB Biotherapeutics, Inc. (SABS)vs ›	$277.29M	0.02	0.11	0.13	0.16
Aurora Cannabis Inc. (ACB)vs ›	$281.53M	0.04	0.11	0.22	0.26
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$267.03M	0.13	0.07	0.16	0.51
Inhibikase Therapeutics, Inc. (IKT)vs ›	$266.71M	0.00	0.00	0.02	0.02
OraSure Technologies, Inc. (OSUR)vs ›	$266.10M	0.04	0.04	0.04	0.03
Fulcrum Therapeutics, Inc. (FULC)vs ›	$282.68M	0.02	0.03	0.04	0.03
Indaptus Therapeutics, Inc. (INDP)vs ›	$283.11M	0.00	0.01	0.01	0.01

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Fate Therapeutics, Inc. (FATE)

$275.21M

0.49

0.39

0.30

0.24

Rocket Pharmaceuticals, Inc. (RCKT)vs ›

$273.53M

0.07

0.06

0.07

Scribe Therapeutics Inc. (SCTX)vs ›

$270.48M

N/A

SAB Biotherapeutics, Inc. (SABS)vs ›

$277.29M

0.02

0.11

0.13

0.16

Aurora Cannabis Inc. (ACB)vs ›

$281.53M

0.04

0.11

0.22

0.26

EyePoint Pharmaceuticals, Inc. (EYPT)vs ›

$267.03M

0.13

0.07

0.16

0.51

Inhibikase Therapeutics, Inc. (IKT)vs ›

$266.71M

0.00

0.02

OraSure Technologies, Inc. (OSUR)vs ›

$266.10M

0.04

0.03

Fulcrum Therapeutics, Inc. (FULC)vs ›

$282.68M

0.02

0.03

0.04

0.03

Indaptus Therapeutics, Inc. (INDP)vs ›

$283.11M

0.00

0.01

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Fate Therapeutics, Inc. (FATE)?

The debt to equity ratio for FATE stock is 0.49.

Is Fate Therapeutics, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.49 is 102% above its 5-year average of 0.24, near the high end of its 5-year range (0.15–0.49).

What is the TTM average debt to equity ratio for Fate Therapeutics, Inc. (FATE)?

The TTM average debt to equity ratio for FATE stock is 0.39.

What is the 3Y average debt to equity ratio for Fate Therapeutics, Inc. (FATE)?

The 3Y average debt to equity ratio for FATE stock is 0.30.

What is the 5Y average debt to equity ratio for Fate Therapeutics, Inc. (FATE)?

The 5Y average debt to equity ratio for FATE stock is 0.24.

What is the 10Y average debt to equity ratio for Fate Therapeutics, Inc. (FATE)?

The 10Y average debt to equity ratio for FATE stock is 0.23.

What is the 15Y average debt to equity ratio for Fate Therapeutics, Inc. (FATE)?

The 15Y average debt to equity ratio for FATE stock is 0.24.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.49
2026-03-31	0.43
2025-12-31	0.38
2025-09-30	0.34
2025-06-30	0.31
2025-03-31	0.29
2024-12-31	0.27
2024-09-30	0.27
2024-06-30	0.25
2024-03-31	0.24
2023-12-31	0.28
2023-09-30	0.26
2023-06-30	0.24
2023-03-31	0.23
2022-12-31	0.23
2022-09-30	0.21
2022-06-30	0.19
2022-03-31	0.18
2021-12-31	0.17
2021-09-30	0.15
2021-06-30	0.15
2021-03-31	0.14
2020-12-31	0.25
2020-09-30	0.20
2020-06-30	0.17
2020-03-31	0.35
2019-12-31	0.11
2019-09-30	0.15
2019-06-30	0.33
2019-03-31	0.29
2018-12-31	0.09
2018-09-30	0.09
2018-06-30	0.29
2018-03-31	0.23
2017-12-31	0.19
2017-09-30	0.32
2017-06-30	0.12
2017-03-31	0.14
2016-12-31	0.15
2016-09-30	0.50
2016-06-30	0.63
2016-03-31	0.53
2015-12-31	0.48
2015-09-30	0.43
2015-06-30	0.39
2015-03-31	0.93
2014-12-31	0.69
2014-09-30	0.30
2014-06-30	0.02
2014-03-31	0.03
2013-12-31	0.03
2013-09-30	-0.39
2013-06-30	-18.05
2013-03-31	13.24
2012-12-31	-0.07
2012-09-30	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.49

2026-03-31

0.43

2025-12-31

0.38

2025-09-30

0.34

2025-06-30

0.31

2025-03-31

0.29

2024-12-31

0.27

2024-09-30

0.27

2024-06-30

0.25

2024-03-31

0.24

2023-12-31

0.28

2023-09-30

0.26

2023-06-30

0.24

2023-03-31

0.23

2022-12-31

0.23

2022-09-30

0.21

2022-06-30

0.19

2022-03-31

0.18

2021-12-31

0.17

2021-09-30

0.15

2021-06-30

0.15

2021-03-31

0.14

2020-12-31

0.25

2020-09-30

0.20

2020-06-30

0.17

2020-03-31

0.35

2019-12-31

0.11

2019-09-30

0.15

2019-06-30

0.33

2019-03-31

0.29

2018-12-31

0.09

2018-09-30

0.09

2018-06-30

0.29

2018-03-31

0.23

2017-12-31

0.19

2017-09-30

0.32

2017-06-30

0.12

2017-03-31

0.14

2016-12-31

0.15

2016-09-30

0.50

2016-06-30

0.63

2016-03-31

0.53

2015-12-31

0.48

2015-09-30

0.43

2015-06-30

0.39

2015-03-31

0.93

2014-12-31

0.69

2014-09-30

0.30

2014-06-30

0.02

2014-03-31

0.03

2013-12-31

0.03

2013-09-30

-0.39

2013-06-30

-18.05

2013-03-31

13.24

2012-12-31

-0.07

2012-09-30

0.00

Debt to Equity Ratio: 0.49

FATE Debt to Equity Ratio

FATE Average Debt to Equity Ratio Chart

FATE Current vs Average Debt to Equity Ratio Chart

FATE Debt to Equity Ratio Metrics

FATE Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

FATE Debt to Equity Ratio History

Related Metrics